The Top Line The biggest potential drug launches of 2026
6 snips
Feb 6, 2026 Gabrielle Masson, Fierce journalist and industry analyst covering pharma and biotech business news. She discusses the massive sales forecasts for next-generation obesity drugs from Novo Nordisk and Eli Lilly. Short takes cover the methodology behind the annual launches list, comparisons with prior years, and a roundup of other 2026 candidates across cancer, myeloma, inflammation, kidney disease and essential tremor.
AI Snips
Chapters
Transcript
Episode notes
Market Concentration In Few Big Launches
- Evaluate predicts the top 10 2026 launches could hit nearly $46 billion in annual sales by 2032. This shows analysts expect outsized growth concentrated in a few candidates rather than broad mid-sized launches.
Obesity Drug Expectations Drive Valuations
- Novo Nordisk's Cagresma tops the list with a $17.2 billion 2032 sales projection, reflecting huge expectations for obesity drugs. Analysts' fixation on exact percent weight-loss thresholds can move markets despite clinically meaningful results.
Oral Small Molecules Offer Scaling Edge
- Eli Lilly's oral orforglipron is forecast at $11.8 billion for 2032 and could gain share via easier dosing and manufacturing. Small-molecule oral formulations may scale faster than peptide-based alternatives, offering commercial edge.